Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bruton Tyrosine Kinase Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02195869
What this trial is testing

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Who this might be right for
Graft Versus Host Disease
Pharmacyclics LLC. 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT02213926
What this trial is testing

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma (MCL)
Acerta Pharma BV 124
Large-scale testing (Phase 3)WithdrawnNCT05431179
What this trial is testing

Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Lymphoma, Mantle-CellLymphomaLymphoproliferative Disorders+5 more
Oncternal Therapeutics, Inc
Large-scale testing (Phase 3)Study completedNCT01855750
What this trial is testing

The Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma
Janssen Research & Development, LLC 838
Testing effectiveness (Phase 2)WithdrawnNCT03370185
What this trial is testing

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
SecuraBio
Testing effectiveness (Phase 2)Study completedNCT03088878
What this trial is testing

Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMantle Cell Lymphoma+1 more
Oncternal Therapeutics, Inc 95
Testing effectiveness (Phase 2)Study completedNCT01599949
What this trial is testing

Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Who this might be right for
Mantle Cell Lymphoma
Janssen Research & Development, LLC 120
Testing effectiveness (Phase 2)Study completedNCT04402138
What this trial is testing

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
SCRI Development Innovations, LLC 15
Not applicableStudy completedNCT05555979
What this trial is testing

Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom

Who this might be right for
Chronic Lymphocytic Leukemia
AbbVie 56
Not applicableNot Yet RecruitingNCT07525817
What this trial is testing

A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma

Who this might be right for
Mature B-Cell Lymphoma
Ou Bai, MD/PHD 40
Testing effectiveness (Phase 2)Study completedNCT02169180
What this trial is testing

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Lymphoma, Mantle-cell
Janssen Pharmaceutical K.K. 16
Large-scale testing (Phase 3)Study completedNCT01722487
What this trial is testing

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Pharmacyclics LLC. 269
Testing effectiveness (Phase 2)Study completedNCT05038904
What this trial is testing

Preventing Anaphylaxis With Acalabrutinib

Who this might be right for
Food AllergyFood Allergy Peanut
Johns Hopkins University 10
Post-approval studies (Phase 4)Study completedNCT04042376
What this trial is testing

Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Who this might be right for
Waldenstrom Macroglobulinemia
Janssen Research & Development, LLC 17
Testing effectiveness (Phase 2)Looking for participantsNCT07271667
What this trial is testing

Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaB-cell Malignancies
Curis, Inc. 108
Large-scale testing (Phase 3)Study completedNCT01646021
What this trial is testing

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Who this might be right for
Mantle Cell Lymphoma
Janssen Research & Development, LLC 280
Testing effectiveness (Phase 2)Looking for participantsNCT06812715
What this trial is testing

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

Who this might be right for
Chronic Lymphocytic Leukemia
Peter MacCallum Cancer Centre, Australia 40
Large-scale testing (Phase 3)Study completedNCT03474679
What this trial is testing

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

Who this might be right for
Graft vs Host Disease
Janssen Pharmaceutical K.K. 19
Early research (Phase 1)Looking for participantsNCT04830137
What this trial is testing

NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+5 more
Nurix Therapeutics, Inc. 248
Testing effectiveness (Phase 2)Active Not RecruitingNCT02029443
What this trial is testing

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter's Syndrome+1 more
Acerta Pharma BV 306
Next Page